**Supplementary Table 1. Summary of case reports on SR angioplasty**

| Author (year) | Age (y)/sex | Occlusion site | SR (size) | IST during TSRD | Retrieval after TSRD | Resheath after TSRD | TSRD time (min) | No. of TSRDs | Total no. of procedures | Procedural time (min) | Intraprocedural antiplatelets | Postoperative anticoagulant | sICH | END | Reocclusion within 7 days | mRS score at 90 days |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Raychev (2018) | 92/female | BA | Solitaire FR (4×20 mm) | – | – | + | 15 | 1 | 1 | N/A | N/A | N/A | – | – | – | 0 |
| Moteki et al. (2020) | 44/male | MCA | Trevo Xp (3×20 mm) | – | – | + | 5 | 1 | 2 | N/A | ASA 200 mg CLP 300 mg | N/A | – | – | – | N/A |
| Tanaka et al. (2022) | 73/male | ICA | Solitaire Platinum (6×40 mm) | + | + | – | 30 | 1 | 1 | N/A | ASA 200 mg CLP 150 mg | N/A | – | – | – | 2 |
| Tanaka et al. (2022) | 60/male | ICA | Solitaire Platinum (6×40 mm) | + | + | – | 10 | 2 | 3 | N/A | ASA 200 mg CLP 300 mg | N/A | – | – | – | 0 |
| Morofuji et al. (2023) | 88/male | VA | Solitaire (N/A) | – | – | + | 30 | 1 | 3 | N/A | N/A | N/A | – | – | – | 2 |
| Sen et al. (2024) | 85/male | MCA | Trevo NXT (6×37 mm) | – | + | – | 15 | 1 | 2 | 35 | Ozagrel sodium 80 mg | N/A | – | – | – | 2 |
| Inui et al. (2024) | 79/male | M2 | Solitaire Platinum (3×40 mm) | + | – | + | 30 | 4 | 4 | 174 | ASA 200 mg CLP 300 mg | N/A | – | – | – | 2 |
| Yokoyama et al. (2025) | 80/female | BA | Solitaire X (6×40 mm) | – | – | + | 30 | 1 | 2 | 92 | ASA 200 mg PRA 20mg | N/A | – | – | – | 3 |

Total number of procedures were defined as the total number of device maneuvers, including stent retrieval passes, TSRD deployments, and rescue balloon angioplasty. Procedural time was measured from groin puncture to final reperfusion. Hemorrhagic complications were classified according to the Heidelberg bleeding classification, and symptomatic intracerebral hemorrhage was defined as any intracranial hemorrhage accompanied by a worsening NIHSS score of ≥4 within 24 hours. END was defined as an increase of ≥4 points in the NIHSS score within 24 hours after EVT. Reocclusion was defined as recurrent occlusion of the treated artery confirmed on follow-up vascular imaging within 7 days after EVT. SR, stent retriever; IST, in-stent thrombotic sign; TSRD, temporary stent retriever deployment; sICH, symptomatic intracranial hemorrhage; END, early neurological deterioration; mRS, modified Rankin Scale; BA, basilar artery; N/A, not applicable; MCA, middle cerebral artery; ASA, aspirin; CLP, clopidgrel; ICA, internal carotid artery; VA, vertebral artery; PRA, prasugrel; NIHSS, National Institutes of Health Stroke Scale; EVT, endovascular therapy.

## REFERENCES


1. Raychev R. Stent-retriever angioplasty with in-situ aspiration in a patient with acute basilar artery occlusion due to underlying atherosclerosis. *J Clin Case Rep* 2018;8:1163
2. Moteki Y, Shimizu A, Nakamura A, Yamahata H, Kobayashi T. Mild angioplasty with a stent retriever for acute atherothrombotic middle cerebral artery occlusion: a case report. *Interdiscip Neurosurg* 2020;22:100856
3. Tanaka T, Michiwaki Y, Yamane F, Wakamiya T, Sashida R, Fujiwara R, et al. Stent retriever angioplasty for acute atherosclerotic occlusion of internal carotid artery: a case report. *Surg Neurol Int* 2022;13:482
4. Morofuji Y, Tateishi Y, Izumo T, Matsuo T. Stent retriever angioplasty for acute atherosclerotic occlusion of vertebral artery. *Clin Neurol Neurosurg* 2023;232:107842
5. Sen S, Nagao Y, Inatomi Y, Nakajima M, Yonehara T. Stent retriever angioplasty for acute restenosis of the middle cerebral artery. *Cureus* 2024;16:e59696
6. Inui R, Abe S, Ishiyama H, Tsutsui T, Yamamoto A, Shiomi Y, et al. Stent retriever angioplasty for intracranial atherosclerotic disease-related medium vessel occlusion: a case report and literature review. *J Neuroendovasc Ther* 2024;18:273-277
7. Yokoyama R, Haraguchi K, Nakamura Y, Imataka S, Saga T, Hanyu N, et al. A case of acute atherosclerotic basilar artery occlusion treated by angioplasty with a stent retriever and combined antithrombotic therapy. *J Neuroendovasc Ther* 2025;19:2024-0056